Atypical Hemolytic Uremic Syndrome after Sars-CoV-2 Infection

Report of Two Cases

Bibliographic Data

ID15465607
AuthorsIwona Smarz-Widelska (Cardinal Stefan Wyszynski University in Warsaw), Małgorzata Syroka-Główka (Cardinal Stefan Wyszynski University in Warsaw), Joanna Janowska-Jaremek (Cardinal Stefan Wyszynski University in Warsaw), Małgorzata Kozioł (0000-0001-9079-8594, Medical University of Lublin, corresponding author), Wojciech Załuska (0000-0001-6043-3236, Medical University of Lublin)
Year2022
Volume19
Issue18
Pages11437-11437
Publication date2022-09-11
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph191811437
PMID36141710
OpenAlexW4295743218
LanguageEN
References cited25

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease causing systemic thrombotic microangiopathy (TMA) due to the fact of complement dysregulation. Immune activation by viruses, including SARS-CoV-2, can lead to the development of an episode of aHUS against a background of genetic dysregulation in the complement pathway. This paper presents an analysis of two cases of aHUS-siblings diagnosed with familial disease, with a genetic predisposition to aHUS, in whom infection with SARS-CoV-2 was a strong trigger of disease recurrence. The quick recognition and treatment with eculizumab in the early stage of the disease resulted in a rapid improvement in clinical conditions and laboratory parameters

Atypical hemolytic uremic syndrome · Complement system · Disease · Eculizumab · Genetic predisposition · Immune dysregulation · Immune system · Thrombotic microangiopathy · Complement system in diseases · Medicine · Mosquito-borne diseases and control · SARS-CoV-2 and COVID-19 Research · Immunology · Internal Medicine

Tools

Open DOIOpen Access